Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV003139263 | SCV003820355 | uncertain significance | Combined oxidative phosphorylation defect type 20 | 2021-01-25 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003139263 | SCV004039378 | pathogenic | Combined oxidative phosphorylation defect type 20 | 2023-08-24 | criteria provided, single submitter | clinical testing | Variant summary: VARS2 c.1346G>A (p.Trp449X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 0.00015 in 250068 control chromosomes (gnomAD), predominantly at a frequency of 0.0012 within the South Asian subpopulation in the gnomAD database. To our knowledge, no occurrence of c.1346G>A in individuals affected with Combined Oxidative Phosphorylation Defect Type 20 and no experimental evidence demonstrating its impact on protein function have been reported. One ClinVar submitter has assessed the variant since 2014, and classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as pathogenic. |
Clinical Genetics Laboratory, |
RCV004697269 | SCV005198978 | likely pathogenic | not provided | 2022-07-28 | criteria provided, single submitter | clinical testing |